Recently, more and more studies have reported that SASP-mediated xCT down-regulation results in a variety of tumour suppressive effects in lung cancer (JI et al., 2018), gatric cancer (ZHUANG et al., 2021) and pancreatic cancer (HUNG et al., 2020). This evidence concerns the gene SLC7A11 and familial pancreatic carcinoma.